Key Developments in Pivotal Trial & Innovation Study
Filed with ASX · · 4 pages · English
Summary by 6ix AI
EMvision Medical Devices Ltd. provides an update on its Pivotal Trial and Continuous Innovation Study for its emu™ bedside brain scanner. Five of the six trial sites are now actively enrolling and scanning patients, with the sixth site preparation underway. The company has also received approval to start a Continuous Innovation Study at two hospitals in Australia. This study aims to enhance device innovation and support indication expansion for traumatic brain injury.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
EMvision Medical Devices Ltd. on 6ix
Story so far
Earlier from EMvision Medical Devices
- EMVision Awarded $5m Non-Dilutive Government Grant
- Additional Pivotal Trial Site Activations
- Enhanced Algorithm Performance From Continuous Innovation
- Activation of Second US Pivotal Trial Site, Mayo Clinic
- Emu Pivotal Validation Trial Commences
Later from EMvision Medical Devices
- First Responder Program Advanced & Grant Milestone Achieved
- EMVision Awarded $3m Grant For Regional Benefits Study
- UCLA Health Activation & Continuous Innovation Study Update
- Appendix 4E & Annual Report to 30 June 2025
- Trading Halt
Follow EMvision Medical Devices into a list and get an email when it puts out news.
Follow EMvision Medical Devices